CN110691782A - 作为brd4和jak2双重抑制剂的稠合的嘧啶化合物及其使用方法 - Google Patents

作为brd4和jak2双重抑制剂的稠合的嘧啶化合物及其使用方法 Download PDF

Info

Publication number
CN110691782A
CN110691782A CN201780085399.XA CN201780085399A CN110691782A CN 110691782 A CN110691782 A CN 110691782A CN 201780085399 A CN201780085399 A CN 201780085399A CN 110691782 A CN110691782 A CN 110691782A
Authority
CN
China
Prior art keywords
compound
alkyl
cancer
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780085399.XA
Other languages
English (en)
Chinese (zh)
Inventor
拉姆·尚卡尔·乌帕达亚雅
拉加瓦·科蒂里
萨钦·马登
桑托什·库马尔·科图里·拉贾亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptose Biosciences Inc
Original Assignee
Aptose Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptose Biosciences Inc filed Critical Aptose Biosciences Inc
Publication of CN110691782A publication Critical patent/CN110691782A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780085399.XA 2016-12-01 2017-12-01 作为brd4和jak2双重抑制剂的稠合的嘧啶化合物及其使用方法 Pending CN110691782A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662428756P 2016-12-01 2016-12-01
US62/428,756 2016-12-01
PCT/CA2017/000258 WO2018098561A1 (en) 2016-12-01 2017-12-01 Fused pyrimidine compounds as brd4 and jak2 dual inhibitors and methods for use thereof

Publications (1)

Publication Number Publication Date
CN110691782A true CN110691782A (zh) 2020-01-14

Family

ID=62241001

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780085399.XA Pending CN110691782A (zh) 2016-12-01 2017-12-01 作为brd4和jak2双重抑制剂的稠合的嘧啶化合物及其使用方法

Country Status (7)

Country Link
US (1) US11279703B2 (enExample)
EP (1) EP3548496A4 (enExample)
JP (1) JP2019536820A (enExample)
KR (1) KR20190135464A (enExample)
CN (1) CN110691782A (enExample)
AU (1) AU2017369753A1 (enExample)
WO (1) WO2018098561A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022083560A1 (zh) * 2020-10-19 2022-04-28 南京药石科技股份有限公司 Tyk2选择性抑制剂及其用途
CN114957248A (zh) * 2022-05-09 2022-08-30 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
WO2022228512A1 (zh) * 2021-04-30 2022-11-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡咯并嘧啶衍生物
WO2023137634A1 (zh) * 2022-01-19 2023-07-27 上海奕拓医药科技有限责任公司 三并环化合物、其制备、药物组合物及应用
WO2023169461A1 (zh) * 2022-03-08 2023-09-14 广州再极医药科技有限公司 一种噻吩并嘧啶类化合物、中间体、其制备方法、组合物和应用
WO2025002355A1 (zh) * 2023-06-29 2025-01-02 成都金瑞基业生物科技有限公司 一种jak2抑制剂的晶型及制备方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3717475B1 (en) 2017-11-20 2023-06-07 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2020051572A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
EP3842435A4 (en) * 2018-09-20 2022-05-11 Hanmi Pharm. Co., Ltd. NEW SULFONAMIDE DERIVATIVE PRESENTING A FUSED PYRIMIDINE SKELETON, HAVING AN INHIBITOR EFFECT OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION
KR102377007B1 (ko) * 2018-09-20 2022-03-22 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체
US20220064146A1 (en) * 2018-12-31 2022-03-03 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN110305140B (zh) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
WO2021030238A2 (en) * 2019-08-09 2021-02-18 Ohm Oncology Method of synthesis of compound for dual inhibition of jak2 and bet
EP3800188A1 (en) 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
GB201914910D0 (en) * 2019-10-15 2019-11-27 Sentinel Oncology Ltd Pharmaceutical compounds
CA3156474A1 (en) * 2019-11-08 2021-05-14 Heptares Therapeutics Limited GPR52 MODULATING COMPOUNDS
US20230055321A1 (en) * 2019-11-22 2023-02-23 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors
GB202113079D0 (en) * 2021-09-14 2021-10-27 Ucl Business Ltd New therapy
AU2022368823A1 (en) * 2021-10-19 2024-05-16 Impact Therapeutics (Shanghai), Inc. Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1340054A (zh) * 1999-02-18 2002-03-13 诺瓦提斯公司 2－氨基－6－苯胺基－嘌呤及其作为药物的用途
WO2009062258A1 (en) * 2007-11-15 2009-05-22 Cytopia Research Pty Ltd N-containing heterocyclic compounds
CA2723185A1 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010071885A1 (en) * 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
WO2011062372A2 (en) * 2009-11-19 2011-05-26 Korea Institute Of Science And Technology 2, 4, 7 -substituted thieno [3, 2 -d] pyrimidine compounds as protein kinase inhibitors
CN102458581A (zh) * 2009-05-22 2012-05-16 因塞特公司 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
US20120277424A1 (en) * 2009-10-22 2012-11-01 Korea Institute Of Science And Technology 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2015151006A1 (en) * 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
US20150336982A1 (en) * 2013-01-18 2015-11-26 Shanghai Chemexplorer Co., Ltd. Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof
WO2016022460A1 (en) * 2014-08-03 2016-02-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Potent dual brd4-kinase inhibitors as cancer therapeutics
CN107698603A (zh) * 2016-08-09 2018-02-16 厦门大学 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704386B1 (ko) * 2013-06-28 2017-02-08 한국과학기술연구원 티에노[3,2-ｄ]피리미딘 유도체의 Ｔ315Ｉ-Ｂｃｒ-Ａｂｌ 점돌연변이종의 저해 활성
AU2016220219B2 (en) * 2015-02-17 2020-05-14 Neupharma, Inc. Certain chemical entities, compositions, and methods

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1340054A (zh) * 1999-02-18 2002-03-13 诺瓦提斯公司 2－氨基－6－苯胺基－嘌呤及其作为药物的用途
WO2009062258A1 (en) * 2007-11-15 2009-05-22 Cytopia Research Pty Ltd N-containing heterocyclic compounds
CA2723185A1 (en) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010071885A1 (en) * 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
CN102458581A (zh) * 2009-05-22 2012-05-16 因塞特公司 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
US20120277424A1 (en) * 2009-10-22 2012-11-01 Korea Institute Of Science And Technology 2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors
WO2011062372A2 (en) * 2009-11-19 2011-05-26 Korea Institute Of Science And Technology 2, 4, 7 -substituted thieno [3, 2 -d] pyrimidine compounds as protein kinase inhibitors
US20150336982A1 (en) * 2013-01-18 2015-11-26 Shanghai Chemexplorer Co., Ltd. Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2015151006A1 (en) * 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2016022460A1 (en) * 2014-08-03 2016-02-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Potent dual brd4-kinase inhibitors as cancer therapeutics
CN107698603A (zh) * 2016-08-09 2018-02-16 厦门大学 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRAIG A. ZIFICSAK ET AL.: "Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
陆婷婷等: "PDE4/PDE7双重抑制剂的研究进展", 《沈阳药科大学学报》 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022083560A1 (zh) * 2020-10-19 2022-04-28 南京药石科技股份有限公司 Tyk2选择性抑制剂及其用途
CN116249526A (zh) * 2020-10-19 2023-06-09 南京药石科技股份有限公司 Tyk2选择性抑制剂及其用途
CN116249526B (zh) * 2020-10-19 2025-11-28 南京药石科技股份有限公司 Tyk2选择性抑制剂及其用途
WO2022228512A1 (zh) * 2021-04-30 2022-11-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡咯并嘧啶衍生物
CN117295743A (zh) * 2021-04-30 2023-12-26 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡咯并嘧啶衍生物
WO2023137634A1 (zh) * 2022-01-19 2023-07-27 上海奕拓医药科技有限责任公司 三并环化合物、其制备、药物组合物及应用
CN118574832A (zh) * 2022-01-19 2024-08-30 上海奕拓医药科技有限责任公司 三并环化合物、其制备、药物组合物及应用
WO2023169461A1 (zh) * 2022-03-08 2023-09-14 广州再极医药科技有限公司 一种噻吩并嘧啶类化合物、中间体、其制备方法、组合物和应用
CN114957248A (zh) * 2022-05-09 2022-08-30 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
WO2025002355A1 (zh) * 2023-06-29 2025-01-02 成都金瑞基业生物科技有限公司 一种jak2抑制剂的晶型及制备方法

Also Published As

Publication number Publication date
KR20190135464A (ko) 2019-12-06
US11279703B2 (en) 2022-03-22
EP3548496A4 (en) 2020-05-13
AU2017369753A1 (en) 2019-07-18
WO2018098561A1 (en) 2018-06-07
US20200095252A1 (en) 2020-03-26
EP3548496A1 (en) 2019-10-09
JP2019536820A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
CN110691782A (zh) 作为brd4和jak2双重抑制剂的稠合的嘧啶化合物及其使用方法
US11642342B2 (en) Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
US11485713B2 (en) Androgen receptor modulators and methods for their use
JP2022504949A (ja) アンドロゲン受容体モジュレーター及びその使用方法
CA3134545A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
JP7688000B2 (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
JP2010502651A (ja) セリン−トレオニンタンパク質キナーゼおよびｐａｒｐ調節因子
JP2021527112A (ja) ニューロキニン−１受容体アンタゴニストとしての化合物およびその使用
CN107530350A (zh) 细胞坏死抑制剂及相关方法
US20250382309A1 (en) Methods and materials for increasing transcription factor eb polypeptide levels
WO2017210685A1 (en) Pyradazinone derivatives and the compositions and methods of treatment regarding the same
US10550103B2 (en) Dual inhibitors of PARP1 and CDK
TWI755418B (zh) 聯芳組成物和調控激酶級聯之方法
US20200317674A1 (en) Pyrazolopyrimidine derivatives and the compositions and methods of treatment regarding the same
US20120184509A1 (en) Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof
KR20250152056A (ko) Adar1 억제제 및 이의 이용 방법
US10889553B2 (en) Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
TW308587B (enExample)
JP7145154B2 (ja) ロイコトリエンａ４ヒドロラーゼの阻害剤
HK40010526A (en) Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
BR112021007222B1 (pt) Compostos moduladores de receptor de androgênio, seus usos, e composições farmacêuticas
JPH034068B2 (enExample)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200114